Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis
A technology of dependent dermatitis and active substances, which is applied in the field of application of lipid active substances of Camellia plants in the treatment of hormone-dependent dermatitis, and can solve the problems of slow recovery of patients, thinning of the stratum corneum, and damage of the skin barrier, etc. problems, to achieve the effect of improving human health care and quality of life, facilitating the formation of wound epithelial cells, and reducing adverse stimuli
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0017] Example 1: Clinical observation of 30 cases of facial hormone-dependent dermatitis treated with lipid active substances
[0018] 1 Materials and methods
[0019] 1 Inclusion criteria
[0020] (1) There is a history of external use of hormone products on fixed sites for more than half a month;
[0021] (2) The original disease or skin lesion recurs or aggravates 2 to 10 days after stopping the use of hormone-containing products; hormone dependence occurs (rebound after stopping the drug, the original disease or skin lesion recurs or aggravates, and the symptoms are relieved after repeated use) );
[0022] (3) Typical skin lesions: diverse skin lesions with erythema, papules, dryness and desquamation as the basic lesions, which cannot be explained by other skin diseases;
[0023] (4) Subjective symptoms: conscious local itching, burning pain, tightness and swelling, or dry discomfort, which are aggravated by heat and relieved by cold.
[0024] Those who have (1), (2) ...
Embodiment 2
[0058] Example 2: Clinical Observation of 50 Cases of Facial Hormone-Dependent Dermatitis Treated by Lipid Actives
[0059] 1 Materials and methods
[0060] 1 Inclusion criteria are the same as in Example 1
[0061] 2 get rid of the case with embodiment 1
[0062] 3 General Information
[0063]A total of 100 patients, including 22 males and 78 females; aged 21 to 50 years old; had external use of betamethasone, clobetasone, etc., an average of 7.3 months (1 month to 12 years).
[0064] 100 patients were randomly divided into treatment group [50 cases, age (32.2±5.99) years] and control group [50 cases, age (31.82±7.52) years]. There was no significant difference between the treatment group and the control group in terms of age, sex, course of disease and symptom scores, and they were comparable.
[0065] 4 treatment methods
[0066] Treatment group: self-made lipid actives, made into light yellow oily liquid, enterprise standard, accelerated stability test results show th...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com